Merck Mevacor Pediatric Exclusivity To Be Revisited By FDA By July 17
Executive Summary
FDA's Pediatric Exclusivity Board is expected to reevaluate the pediatric exclusivity application for Merck's cholesterol drug Mevacor (lovastatin) by July 17.
You may also be interested in...
Merck Mevacor Exclusivity Will Run Until Dec. 15 Following FDA Reversal
FDA is granting Merck pediatric exclusivity for Mevacor (lovastatin) through Dec. 15 following consideration of clarified data submitted by the company.
Merck Mevacor Exclusivity Will Run Until Dec. 15 Following FDA Reversal
FDA is granting Merck pediatric exclusivity for Mevacor (lovastatin) through Dec. 15 following consideration of clarified data submitted by the company.
Merck Mevacor Pediatric Exclusivity Gets July 3 Hearing; 5 Generics Stayed
The D.C. federal court is scheduled to hear arguments on Merck's Mevacor pediatric exclusivity application July 3.